NICE u-turn backs Stelara for UC
admin 28th April 2020 Uncategorised 0Stelara is the first biologic therapy for UC that targets interleukin (IL)-12 and IL-23 cytokines More: NICE u-turn backs Stelara for UC Source: News
read more
Stelara is the first biologic therapy for UC that targets interleukin (IL)-12 and IL-23 cytokines More: NICE u-turn backs Stelara for UC Source: News
read moreKevzara had “no notable benefit” on clinical outcomes when combining the severe and critical groups versus placebo More: Mixed results for Sanofi's Kevzara COVID-19 trial Source: News
read moreFetcroja is the first treatment to provide coverage against all Gram-negative pathogens considered of critical priority More: EC approves Shionogi's new antibiotic Fetcroja Source: News
read moreWith the spotlight on the global pharmaceutical supply chain, a lockdown at a major Indian manufacturing hub earlier this month caused waves of unrest. Now, weeks later, that hub is back up and running—but concerns about India’s control over the
read moreSanofi and Regeneron may be late to the PD-1/PD-L1 party with sixth-to-market Libtayo, but they sure don’t intend to miss out on the lucrative lung cancer market. And with just-released data, they’re on their way to a chance to wrest
read moreGilead Sciences and federal authorities have been locked in a high-stakes fight over patents on an HIV prevention drug, and now Gilead has filed the latest salvo. In a new lawsuit, the Big Biotech claims the U.S. secured its patents by breaching
read more© 1994 - 2026 B.M. Pharmaceuticals